Interferons as potential adjuvants in prophylactic vaccines

Expert Opinion on Biological Therapy

Volumn 10, Issue 10, 2010, Pages 1489-1500

  Toporovski, Roberta ^a   Morrow, Matthew P ^a   Weiner, David B ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

adjuvants; cytokines; IFNs; TH1 cells; vaccines

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; DNA VACCINE; GAMMA INTERFERON; HEPATITIS B VACCINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOLOGICAL ADJUVANT; INFLUENZA VACCINE; INTERFERON; INTERFERON LAMBDA; RABIES VACCINE; RECOMBINANT HEPATITIS B VACCINE; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ANTIVIRAL ACTIVITY; DRUG EFFICACY; DRUG SAFETY; HEPATITIS B; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOMODULATION; INFLUENZA; NONHUMAN; RABIES; REVIEW; TH1 CELL; VIRUS INFECTION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; HUMANS; INTERFERON-ALPHA; INTERFERON-BETA; INTERFERON-GAMMA; INTERFERONS; INTERLEUKINS; TH1 CELLS; VACCINES;

ANIMALIA;

EID: 77956681345     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2010.521495     Document Type: Review

References (81)

1. Isaacs A, Lindenmann J. Virus interference. I. The interferon. Proc R Soc Lond B 1957;147:258-267
2. Pestka S, Krause C, Walter M. Interferons, interferon-like cytokines, and their receptors. Immunol Rev 2004;202:8-32
3. Pestka S, Langer J, Zoon K, Samuel C. Interferons and their actions. Annu Rev Biochem 1987;56:727-777
4. Chen J, Baig E, Fish E. Diversity and relatedness among the type I interferons. J Interferon Cytokine Res 2004;24:687-698
5. Pestka S, Kotenko S, Muthukumaran G. The human interferon alpha species and hybrid proteins. Semin Oncol 1997;24:S9-4-17
6. Wilkins C, Gale M Jr. Recognition of viruses by cytoplasmic sensors. Curr Opin Immunol 2010;22(1):41-47
7. Ortaldo J, Mantovani A, Hobbs D. Effects of several species of human leukocyte interferon on cytotoxic activity of NK cells and monocytes. Int J Cancer 1983;31:285-289
8. Ortaldo J, Mason A, Rehberg E, Moschera J. Effects of recombinant and hybrid recombinant human leukocyte interferons on cytotoxic activity of natural killer cells. J Biol Chem 1983;258:15011-15015
9. Ortaldo J, Herberman R, Harvey C. A species of human a interferon that lacks the ability to boost human natural killer activity. Proc Natl Acad Sci USA 1984;81:4926-4929
10. Rehberg E, Kelder B, Hoal E, Pestka S. Specific molecular activities of recombinant and hybrid leukocyte interferons. J Biol Chem 1982;257:11497-11502
11. Herberman R, Ortaldo J, Mantovani A. Effect of human recombinant interferon on cytotoxic activity of natural killer (NK) cells and monocytes. Cell Immunol 1882;67:160-167
12. Greiner J, Hand P, Noguchi P, Fisher P. Enhanced expression of surface tumor-associated antigens on human breast and colon tumor cells after recombinant human leukocyte a-interferon treatment. Cancer Res 1984;44:3208-3214
13. Greiner J, Schlom J, Pestka S, Langer J. Modulation of tumor associated antigen expression and shedding by recombinant human leukocyte and fibroblast interferons. Pharmacol Ther 1985;31:209-236
14. Greiner J, Guadagni F, Noguchi P, Pestka S. Recombinant interferon enhances monoclonal antibody-targeting carcinoma lesions in vivo. Science 1987;235:895-898
15. Basham T, Bourgeade M, Creasey A. Interferon increases HLA synthesis in melanoma cells: interferon-resistant and-sensitive cell lines. Proc Natl Acad Sci USA 1982;79:3265-3269
16. Dolei A, Capobianchi M, Ameglio F. Human interferon-g enhances the expression of class I and class II major histocompatibility complex products in neoplastic cells more effectively than interferon-a and interferon-b. Infect Immun 1983;40:172-176
17. Ozzello L, DeRosa CM, Habif DV, et al. Up-regulation of a tumor-associated antigen (TAG-72) by interferons alpha and gamma in patients with cutaneous breast cancer recurrences. Int J Oncol 1995;6:985-991
18. Clemens MJ. Interferons and apoptosis. J Interferon Cytokine Res 2003;23:277-292
19. Keay S, Grossberg SE. Interferon inhibits the conversion of 3T3-L1 mouse fibroblasts into adipocytes. Proc Natl Acad Sci USA 1980;77:4099-4103
20. Fisher P, Hermo H Jr, Prignoli D. Hybrid recombinant human leukocyte interferon inhibits differentiation in murine B-16 melanoma cells. Biochem Biophys Res Commun 1984;119:108-115
21. Fisher P, Prignoli D, Hermo H Jr. Effects of combined treatment with interferon and mezerein on melanogenesis and growth in human melanoma cells. J Interferon Res 1985;5:11-22
22. Fidler IJ. Regulation of neoplastic angiogenesis. J Natl Cancer Inst Monogr 2001;28:10-14
23. Kerbel R, Folkman J. Clinical translation of angiogenesis inhibitors. Nat Rev Cancer 2002;2:727-739
24. Pestka S, Kotenko S, Muthukumaran G. The interferon gamma (IFN-gamma) receptor: a paradigm for the multichain cytokine receptor. Cytokine Growth Factor Rev 1997;8:189-206
25. Platanias LC, Fish EN. Signaling pathways activated by interferons. Exp Hematol 1999;27:1583-1592
26. Parmar S, Platanias LC. Interferons: mechanisms of action and clinical applications. Curr Opin Oncol 2003;15:431-439
27. Bach E, Aguet M, Schreiber R. The IFN gamma receptor: a paradigm for cytokine receptor signaling. Annu Rev Immunol 1997;15:563-591
28. Billiau A, Matthys P. Interferon-g: a historical perspective. Cytokine Growth Factor Rev 2009;20:97-113
29. Uze G, Monneron D. IL-28 and IL-29: newcomers to the interferon family. Biochimie 2007;89:729-734
30. Kotenko S, Gallagher G, Baurin V, et al. IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. Nat Immunol 2003;4:69-77
31. Platanias, L. Mechanisms of type-I-and type-II-interferon-mediated signalling. Nat Rev Immunol 2005;5:375-386
32. Dumoutier L, Tounsi A, Michiels T. Role of the interleukin (IL)-28 receptor tyrosine residues for antiviral and antiproliferative activity of IL-29/interferon-lambda1: similarities with type I interferon signaling. J Biol Chem 2004;279:32269-32274
33. Meager A, Visvalingam K, Dilger P, et al. Biological activity of interleukins-28 and-29: comparison with type I interferons. Cytokine 2005;31:109-118
34. Roselli M, Guadagni F, Buonomo O, et al. Systemic administration of recombinant interferon alfa in carcinoma patients upregulates the expression of the carcinoma-associated antigens tumor-associated glycoprotein-72 and carcinoembryonic antigen. J Clin Oncol 1996;14(7):2031-2042
35. Milenic D, Roselli M, Brechbiel M, et al. In vivo evaluation of a lead-labeled monoclonal antibody using the DOTA ligand. Eur J Nucl Med 1998;25(5):471-480
36. Gresser I. The antitumor effects of interferon: a personal history. Biochimie 2007;89(6-7):723-728
37. Ferrantini M, Capone I, Belardelli F. Interferon-alpha and cancer: mechanisms of action and new perspectives of clinical use. Biochimie 2007;89(6-7):884-893
38. Hance K, Rogers C, Zaharoff D, et al. The antitumor and immunoadjuvant effects of IFN-alpha in combination with recombinant poxvirus vaccines. Clin Cancer Res 2009;15(7):2387-2396
39. Dahan L, Bonnetain F, Rougier P, et al. Phase III trial of chemotherapy using 5-fluorouracil and streptozotocin compared with interferon alpha for advanced carcinoid tumors: FNCLCC-FFCD 9710. Endocr Relat Cancer 2009;16(4):1351-1361
40. Passalacqua R, Buzio C, Buti S, et al. Phase III, randomised, multicentre trial of maintenance immunotherapy with low-dose interleukin-2 and interferon-alpha for metastatic renal cell cancer. Cancer Immunol Immunother 2010;59(4):553-561
41. He L, Gu J, Tang W, et al. Significant antitumor activity of oncolytic adenovirus expressing human interferon-beta for hepatocellular carcinoma. J Gene Med 2008;10(9):983-992
42. Yamamoto K, Mizutani Y, Nakanishi H, et al. Significant antitumor activity of cationic multilamellar liposomes containing human interferon-beta gene in combination with 5-fluorouracil against human renal cell carcinoma. Int J Oncol 2008;33(3):565-571
43. Brill T, Kubler H, Pohla H, et al. Therapeutic vaccination with an interleukin-2-interferon-gamma-secreting allogeneic tumor vaccine in patients with progressive castration-resistant prostate cancer: a phase I/II trial. Human Gene Ther 2009;20(12):1641-1651
44. Grob P, Joller-Jemelka H, Binswanger U, et al. Interferon as an adjuvant for hepatitis B vaccination in non-and low-responder populations. Eur J Clin Microbiol 1984;3(3):195-198
45. Sturchler D, Zimmer G, Berger R, et al. Interferon-alpha and synthetic peptide malaria sporozoite vaccine in non-immune adults: antibody response after 40 weeks. Bull World Health Organ 1990;68(Suppl):38-41
46. Goldwater P. Randomized comparative trial of interferon-alpha versus placebo in hepatitis B vaccine non-responders and hyporesponders. Vaccine 1994;12(5):410-414
47. Santini S, Lapenta C, Logozzi M, et al. Type I interferon as a powerful adjuvant for monocyte-derived dendritic cell development and activity in vitro and in Hu-PBL-SCID mice. J Exp Med 2000;191(10):1777-1788
48. James C, Abdad M, Mansfield J, et al. Differential activities of alpha/beta IFN subtypes against influenza virus in vivo and enhancement of specific immune responses in DNA vaccinated mice expressing haemagglutinin and nucleoprotein. Vaccine 2007;25(10):1856-1867
49. Bracci L, Canini I, Puzelli S, et al. Type I IFN is a powerful mucosal adjuvant for a selective intranasal vaccination against influenza virus in mice and affects antigen capture at mucosal level. Vaccine 2005;23(23):2994-3004
50. Jiang W, Ren L, Jin N. HIV-1 DNA vaccine efficacy is enhanced by coadministration with plasmid encoding IFN-alpha. J Virol Methods 2007;146(1-2):266-273
51. Day S, Ramshaw I, Ramsay A, Ranasinghe C. Differential effects of the type I interferons alpha4, beta, and epsilon on antiviral activity and vaccine efficacy. J Immunol 2008;180(11):7158-7166
52. O'Brien L, Perkins S, Williams A, et al. Alpha interferon as an adenovirus-vectored vaccine adjuvant and antiviral in Venezuelan equine encephalitis virus infection. J Gen Virol 2009;90(Pt 4):874-882
53. Min W, Lillehoj H, Burnside J, et al. Adjuvant effects of IL-1beta, IL-2, IL-8, IL-15, IFN-alpha, IFN-gamma TGF-beta4 and lymphotactin on DNA vaccination against Eimeria acervulina. Vaccine 2001;20(1-2):267-274
54. Rautenschlein S, Sharma J, Winslow B. Embryo vaccination of turkeys against Newcastle disease infection with recombinant fowlpox virus constructs containing interferons as adjuvants. Vaccine 1999;18:426-433
55. Cheng G, Zhao X, Yan W, et al. Alpha interferon is a powerful adjuvant for a recombinant protein vaccine against foot-and-mouth disease virus in swine, and an effective stimulus of in vivo immune response. Vaccine 2007;25(28):5199-5208
56. Launay O, Grabar S, Bloch F, et al. Effect of sublingual administration of interferon-alpha on the immune response to influenza vaccination in institutionalized elderly individuals. Vaccine 2008;26(32):4073-4079
57. Rizza P, Capone I, Urbani F, et al. Evaluation of the effects of human leukocyte IFN-alpha on the immune response to the HBV vaccine in healthy unvaccinated individuals. Vaccine 2008;26(8):1038-1049
58. Miquilena-Colina ME, Lozano-Rodriguez T, Garcia-Pozo L, et al. Recombinant interferon-alpha2b improves immune response to hepatitis B vaccination in haemodialysis patients: results of a randomised clinical trial. Vaccine 2009;27(41):5654-5660
59. Mannie M, Abbott D, Blanchfield J. Experimental autoimmune encephalomyelitis in Lewis rats: IFN-beta acts as a tolerogenic adjuvant for induction of neuroantigen-dependent tolerance. J Immunol 2009;182(9):5331-5341
60. Faul E, Wanjalla C, Mcgettigan J, Schnell M. Interferon-beta expressed by a rabies virus-based HIV-1 vaccine vector serves as a molecular adjuvant and decreases pathogenicity. Virology 2008;382(2):226-238
61. Playfair J, De Souza J. Recombinant gamma interferon is a potent adjuvant for a malaria vaccine in mice. Clin Exp Immunol 1987;67:5-10
62. Kumar M, Behera A, Hu J, et al. IFN-gamma and IL-12 plasmid DNAs as vaccine adjuvant in a murine model of grass allergy. J Allergy Clin Immunol 2001;108(3):402-408
63. Xiang Z, Ertl H. Manipulation of the immune response to a plasmid-encoded viral antigen by coinoculation with plasmids expressing cytokines. Immunity 1995;2(2):129-135
64. Xiang Z, He Z, Wang Y, Ertl H. The effect of interferon-gamma on genetic immunization. Vaccine 1997;15(8):896-898
65. Pasquini S, Xiang Z, Wang Y, et al. Cytokines and costimulatory molecules as genetic adjuvants. Immunol Cell Biol 1997;75(4):397-401
66. Maecker H, Umetsu D, DeKruyff R, Levy S. DNA vaccination with cytokine fusion constructs biases the immune response to ovalbumin. Vaccine 1997;15(15):1687-1696
67. Lowenthal J, O'Neil T, Broadway M, et al. Coadministration of IFN-gamma enhances antibody responses in chickens. J Interferon Cytokine Res 1998;18(8):617-622
68. Ohlschlager P, Quetting M, Alvarez G, et al. Enhancement of immunogenicity of a therapeutic cervical cancer DNA-based vaccine by co-application of sequence-optimized genetic adjuvants. Int J Cancer 2009;125(1):189-198
69. Kim J, Yang J, Montaner L, et al. Coimmunization with IFN-gamma or IL-2, but not IL-13 or IL-4 cDNA can enhance Th1-type DNA vaccine-induced immune responses in vivo. J Interferon Cytokine Res 2000;20(3):311-319
70. Abaitua F, Rodriguez J, Garzon A, et al. Improving recombinant MVA immune responses: potentiation of the immune responses to HIV-1 with MVA and DNA vectors expressing Env and the cytokines IL-12 and IFN-gamma. Virus Res 2006;116(1-2):11-20
71. Park J, Sung H, Yoon B, Kwon H. Protection of chicken against very virulent IBDV provided by in ovo priming with DNA vaccine and boosting with killed vaccine and the adjuvant effects of plasmid-encoded chicken interleukin-2 and interferon-gamma. J Vet Sci 2009;10(2):131-139
72. Long JE, Huang LN, Qin ZQ, et al. IFN-gamma increases efficiency of DNA vaccine in protecting ducks against infection. World J Gastroenterol 2005;11(32):4967-4973
73. Kim J, Yang J, Manson K, Weiner D. Modulation of antigen-specific cellular immune responses to DNA vaccination in rhesus macaques through the use of IL-2, IFN-gamma, or IL-4 gene adjuvants. Vaccine 2001;19(17-19):2496-2505
74. Chow Y, Chiang B, Lee Y, et al. Development of Th1 and Th2 populations and the nature of immune responses to hepatitis B virus DNA vaccines can be modulated by codelivery of various cytokine genes. J Immunol 1998;160(3):1320-1329
75. Pertmer T, Oran A, Madorin C, Robinson H. Th1 genetic adjuvants modulate immune responses in neonates. Vaccine 2001;19(13-14):1764-1771
76. Lena P, Villinger F, Giavedoni L, et al. Co-immunization of rhesus macaques with plasmid vectors expressing IFN-gamma, GM-CSF, and SIV antigens enhances anti-viral humoral immunity but does not affect viremia after challenge with highly pathogenic virus. Vaccine 2002;20(Suppl 4):A69-79
77. Nimal S, McCormick A, Thomas M, Heath A. An interferon gamma-gp120 fusion delivered as a DNA vaccine induces enhanced priming. Vaccine 2005;23(30):3984-3990
78. Iida T, Kuwata T, Ui M, et al. Augmentation of antigen-specificcytokine responses in the early phase of vaccination with a live-attenuated simian/human immunodeficiency chimeric virus expressing IFN-gamma. Arch Virol 2004;149(4):743-757
79. Kaneyasu K, Kita M, Ohkura S, et al. Protective efficacy of nonpathogenic nef-deleted SHIV vaccination combined with recombinant IFN-gamma administration against a pathogenic SHIV challenge in rhesus monkeys. Microbiol Immunol 2005;49(12):1083-1094
80. Morrow MP, Pankhong P, Laddy D, et al. Comparative ability of IL-12 and IL-28B to regulate Treg populations and enhance adaptive cellular immunity. Blood 2009;113(23):5868-5877
81. Morrow MP, Yan J, Pankhong P, et al. IL-28B/IFN-l3 Drives Granzyme B Loading and Significantly Increases CTL Killing Activity in Macaques. Mol Ther 2010 advance online publication, June 22, 2010; doi:10.1038/mt.2010.118